In immunotherapy, addition of anti-PD-1 or anti-PD-L1 blocks the ability of tumor cells to trigger T cell exhaustion, thereby potentiating T cell mediated anti-tumor immunity. This evidence concerns the gene PDCD1 and neoplasm.